Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.
Venous Thromboembolism|Cancer
DRUG: Rivaroxaban 10 MG
Major VTE prevention, Number of Major VTE's in patient population, 90 days (± 3 days) of randomization|Episodes of Major Bleeding, Number of participants who had a major bleed, 90 days (± 3 days) of randomization
Number of participants with Clinically Relevant Non-Major Bleeding (CRNMB), As defined by ISTH, 90 days (± 3 days) of randomization|Number of patients who had a fatal VTE, Fatal VTE, 90 days (± 3 days) of randomization|Number of patients who benefitted from using the experimental intervention, Composite of major VTE and major bleeding, 90 days (± 3 days) of randomization|PE, Incidental and Symptomatic, 90 days (± 3 days) of randomization|Proximal CVC VTE, Incidental and symptomatic proximal (axillary vein or more proximal) upper extremity CVC-related DVT, 90 days (± 3 days) of randomization|Distal CVC VTE, Incidental and symptomatic distal (brachial vein) or proximal (axillary vein or more proximal) upper extremity CVC-related DVT, 90 days (± 3 days) of randomization|Proximal Lower extremity DVT, Incidental and symptomatic proximal (popliteal vein or more proximal) lower extremity DVT, 90 days (± 3 days) of randomization|Distal Lower extremity DVT, Incidental and symptomatic distal or proximal (popliteal vein or more proximal) lower extremity DVT, 90 days (± 3 days) of randomization|Number of participants with Unusual site thrombosis including: splanchnic vein (portal, splenic, superior mesenteric, inferior mesenteric, hepatic) cerebral vein, renal or gonadal vein thromboses, Unusual site thrombosis including: splanchnic vein (portal, splenic, superior mesenteric, inferior mesenteric, hepatic) cerebral vein, renal or gonadal vein thromboses, 90 days (± 3 days) of randomization|Number of participants with Superficial upper or lower extremity vein thrombosis, Superficial upper or lower extremity vein thrombosis, 90 days (± 3 days) of randomization|Number of participants with an arterial thromboembolic event including: MI, stroke, peripheral arterial disease, Arterial thromboembolic events defined as a diagnostically confirmed final clinical diagnosis of myocardial infarction, stroke or peripheral arterial disease involving the following arterial vascular beds: carotid, upper or lower extremity, gastrointestinal tract, liver, spleen, or kidney, 90 days (± 3 days) of randomization|CVC Life-span, Life span of inserted CVC, 90 days (± 3 days) of randomization|Number of patients with CVC occlusion occurring after the start of therapy, defined as an obstruction of the CVC lumen that prevents or limits the ability to flush, withdraw blood and/or administer solutions or medications., CVC occlusion occurring after the start of therapy, defined as an obstruction of the CVC lumen that prevents or limits the ability to flush, withdraw blood and/or administer solutions or medications., 90 days (± 3 days) of randomization|Number of patients with CVC-related blood stream infection defined as the presence of bacteremia originating from the CVC according to the definition from the Centers for Disease Control and Prevention, CVC-related blood stream infection defined as the presence of bacteremia originating from the CVC according to the definition from the Centers for Disease Control and Prevention, 90 days (± 3 days) of randomization|Number of participants who passed away during the trial, Overall mortality, 90 days (± 3 days) of randomization|EQ-5D-5L Health-related quality of life, Health-related quality of life, 90 days (± 3 days) of randomization|ICER, Incremental cost-effectiveness ratio (ICER) at one year, 1 Year
TRIM-Line is a double blind randomized controlled trial comparing rivaroxaban 10mg po daily vs placebo in patients with active cancer and indwelling CVC. This will involve 9 centers across Canada.